How much is Gemini Therapeutics worth in 2026?

Gemini Therapeutics has a current valuation of N/A based on their PIPE round and secondary market data.

How much funding has Gemini Therapeutics raised?

Gemini Therapeutics has raised N/A in total funding across 1 funding rounds.

Gemini Therapeutics

Drug Discovery

Gemini Therapeutics valuation and funding history | Last updated: February 5, 2021 | 1 funding rounds

Current Valuation

N/A

As of February 5, 2021

Total Funding Raised

N/A

Across 1 round

Last Round

PIPE

$95.0M

Last Funding

Feb 2021

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
February 5, 2021	PIPE	$95.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Gemini Therapeutics is currently valued at N/A as of February 5, 2021.

Track Gemini Therapeutics Valuation Updates

Get notified when Gemini Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Gemini Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Gemini Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Gemini Therapeutics Worth in 2026?

Gemini Therapeutics is a leading private company in the Drug Discovery sector. Track Gemini Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Gemini Therapeutics Valuation is Determined

Private company valuations like Gemini Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.